1. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al.
Understanding the tumor immune microenvironment (TIME) for effective therapy.
Nat Med (2018) 24:541–50. doi: 10.1038/s41591-018-0014-x
10. Murata Y, Saito Y, Kotani T, Matozaki T. CD47-signal regulatory protein a
signaling system and its application to cancer immunotherapy. Cancer Sci (2018)
109:2349–57. doi: 10.1111/cas.13663
2. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor
microenvironment. Nat Immunol (2013) 14:1014–22. doi: 10.1038/ni.2703
11. Matozaki T, Murata Y, Okazawa H, Ohnishi H. Functions and molecular
mechanisms of the CD47–SIRPa signalling pathway. Trends Cell Biol (2009) 19:72–
80. doi: 10.1016/j.tcb.2008.12.001
3. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The
prognostic landscape of genes and infiltrating immune cells across human cancers. Nat
Med (2015) 21:938–45. doi: 10.1038/nm.3909
12. Feng M, Jiang W, Kim BYS, Zhang CC, Fu Y-X, Weissman IL. Phagocytosis
checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer (2019) 19:568–
86. doi: 10.1038/s41568-019-0183-z
4. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated
macrophages as treatment targets in oncology. Nat Rev Clin Oncol (2017) 14:399–416.
doi: 10.1038/nrclinonc.2016.217
13. Murata Y, Tanaka D, Hazama D, Yanagita T, Saito Y, Kotani T, et al. Antihuman SIRPa antibody is a new tool for cancer immunotherapy. Cancer Sci (2018)
109:1300–8. doi: 10.1111/cas.13548
5. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to
therapy. Immunity (2014) 41:49–61. doi: 10.1016/j.immuni.2014.06.010
14. Yanagita T, Murata Y, Tanaka D, Motegi S, Arai E, Daniwijaya EW, et al. AntiSIRPa antibodies as a potential new tool for cancer immunotherapy. JCI Insight (2017)
2:e89140. doi: 10.1172/jci.insight.89140
6. Gül N, van Egmond M. Antibody-dependent phagocytosis of tumor cells by
macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer.
Cancer Res (2015) 75:5008–13. doi: 10.1158/0008-5472.can-15-1330
15. A l l e n T M , B r e h m M A , B r i d g e s S , F e r g u s o n S , K u m a r P ,
Mirochnitchenko O, et al. Humanized immune system mouse models:
progress, challenges and opportunities. Nat Immunol (2019) 20:770–4.
doi: 10.1038/s41590-019-0416-z
7. Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer.
Nat Rev Drug Discovery (2018) 17:887–904. doi: 10.1038/nrd.2018.169
8. Veillette A, Chen J. SIRPa–CD47 immune checkpoint blockade in anticancer
therapy. Trends Immunol (2018) 39:173–84. doi: 10.1016/j.it.2017.12.005
16. Rongvaux A, Takizawa H, Strowig T, Willinger T, Eynon EE, Flavell RA, et al.
Human hemato-lymphoid system mice: current use and future potential for
medicine. Annu Rev Immunol (2013) 31:635–74. doi: 10.1146/annurev-immunol032712-095921
9. Barclay AN, van den Berg TK. The interaction between signal regulatory protein
alpha (SIRPa) and CD47: structure, function, and therapeutic target. Annu Rev
Immunol (2014) 32:25–50. doi: 10.1146/annurev-immunol-032713-120142
Frontiers in Immunology
15
frontiersin.org
Saito et al.
10.3389/fimmu.2023.1294814
17. Saito Y, Shultz LD, Ishikawa F. Understanding normal and Malignant human
hematopoiesis using next-generation humanized mice. Trends Immunol (2020)
41:706–20. doi: 10.1016/j.it.2020.06.004
in diffuse large B-cell lymphoma. EMBO Mol Med (2019) 11:e10576. doi: 10.15252/
emmm.201910576
37. Li Y-L, Shi Z-H, Wang X, Gu K-S, Zhai Z-M. Tumor-associated macrophages
predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral
absolute monocyte count. BMC Cancer (2019) 19:1049. doi: 10.1186/s12885-019-6208-x
18. Walsh NC, Kenney LL, Jangalwe S, Aryee K-E, Greiner DL, Brehm MA, et al.
Humanized mouse models of clinical disease. Annu Rev Pathol (2017) 12:187–215.
doi: 10.1146/annurev-pathol-052016-100332
38. Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis VA. The complex
role of tumor-infiltrating macrophages. Nat Immunol (2022) 23:1148–56. doi: 10.1038/
s41590-022-01267-2
19. Rochere PDL, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E.
Humanized mice for the study of immuno-oncology. Trends Immunol (2018)
39:748–63. doi: 10.1016/j.it.2018.07.001
39. Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in
cancer. Trends Immunol (2019) 40:310–27. doi: 10.1016/j.it.2019.02.003
20. Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, et al.
Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol (2023)
20:192–206. doi: 10.1038/s41571-022-00721-2
40. Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted
therapies for solid tumours. Nat Rev Immunol (2023) 23:106–20. doi: 10.1038/s41577022-00737-w
21. Wang M, Yao L, Cheng M, Cai D, Martinek J, Pan C, et al. Humanized mice in
studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J
(2017) 32:1537–49. doi: 10.1096/fj.201700740r
41. Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell
transcriptional atlas of tumor infiltrating myeloid cells. Cell (2021) 184:792–809.e23.
doi: 10.1016/j.cell.2021.01.010
22. Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL, et al.
Development and function of human innate immune cells in a humanized mouse
model. Nat Biotechnol (2014) 32:364–72. doi: 10.1038/nbt.2858
42. Liberzon A, Birger C, Thorvaldsdó ttir H, Ghandi M, Mesirov JP, Tamayo P. The
molecular signatures database hallmark gene set collection. Cell Syst (2015) 1:417–25.
doi: 10.1016/j.cels.2015.12.004
23. Saito Y, Ellegast JM, Rafiei A, Song Y, Kull D, Heikenwalder M, et al. Peripheral
blood CD34+ cells efficiently engraft human cytokine knock-in mice. Blood (2016)
128:1829–33. doi: 10.1182/blood-2015-10-676452
43. Sadik A, Patterson LFS, Öztürk S, Mohapatra SR, Panitz V, Secker PF, et al. IL4I1
is a metabolic immune checkpoint that activates the AHR and promotes tumor
progression. Cell (2020) 182:1252–1270.e34. doi: 10.1016/j.cell.2020.07.038
24. Voillet V, Berger TR, McKenna KM, Paulson KG, Tan WH, Smythe KS, et al. An
in vivo model of human macrophages in metastatic melanoma. J Immunol (2022)
209:606–20. doi: 10.4049/jimmunol.2101109
44. Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, et al.
Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of
KEAP1. Nature (2018) 556:113–7. doi: 10.1038/nature25986
25. Valenzuela DM, Murphy AJ, Frendewey D, Gale NW, Economides AN,
Auerbach W, et al. High-throughput engineering of the mouse genome coupled with
high-resolution expression analysis. Nat Biotechnol (2003) 21:652–9. doi: 10.1038/
nbt822
45. Su S, Zhao J, Xing Y, Zhang X, Liu J, Ouyang Q, et al. Immune checkpoint
inhibition overcomes ADCP-induced immunosuppression by macrophages. Cell
(2018) 175:442–457.e23. doi: 10.1016/j.cell.2018.09.007
26. Seiffert M, Cant C, Chen Z, Rappold I, Brugger W, Kanz L, et al. Human signalregulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells
and mediates cellular adhesion involving its counterreceptor CD47. Blood (1999)
94:3633–43. doi: 10.1182/blood.V94.11.3633
46. Roca H, Jones JD, Purica MC, Weidner S, Koh AJ, Kuo R, et al. Apoptosisinduced CXCL5 accelerates inflammation and growth of prostate tumor metastases in
bone. J Clin Invest (2017) 128:248–66. doi: 10.1172/jci92466
27. Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, et al. Diffuse large
B-cell lymphoma patient-derived xenograft models capture the molecular and
biological heterogeneity of the disease. Blood (2016) 127:2203–13. doi: 10.1182/
blood-2015-09-672352
47. Sakamoto M, Murata Y, Tanaka D, Kakuchi Y, Okamoto T, Hazama D, et al.
Anticancer efficacy of monotherapy with antibodies to SIRPa/SIRPb1 mediated by
induction of antitumorigenic macrophages. Proc Natl Acad Sci USA (2022) 119:
e2109923118. doi: 10.1073/pnas.2109923118
28. Rafiei A, Wilk CM, Helbling PM, Myburgh R, Saito Y, Haralambieva E, et al.
BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cell-like
histiocytosis in immune-deficient mice. Blood Adv (2020) 4:4912–7. doi: 10.1182/
bloodadvances.2020001926
48. Geeraerts X, Ferná ndez-Garcia J, Hartmann FJ, de GKE, Martens L, Elkrim Y,
et al. Macrophages are metabolically heterogeneous within the tumor
microenvironment. Cell Rep (2021) 37:110171. doi: 10.1016/j.celrep.2021.110171
49. Wculek SK, Heras-Murillo I, Mastrangelo A, Mañanes D, Galá n M, Miguel V,
et al. Oxidative phosphorylation selectively orchestrates tissue macrophage
homeostasis. Immunity (2023) 56:516–530.e9. doi: 10.1016/j.immuni.2023.01.011
29. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR:
ultrafast universal RNA-seq aligner. Bioinformatics (2013) 29:15–21. doi: 10.1093/
bioinformatics/bts635
50. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patientderived tumour xenografts as models for oncology drug development. Nat Rev Clin
Oncol (2012) 9:338–50. doi: 10.1038/nrclinonc.2012.61
30. Love MI, Huber W, Anders S. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol (2014) 15:550. doi: 10.1186/
s13059-014-0550-8
51. Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, et al. CD47
blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. New Engl J Med
(2018) 379:1711–21. doi: 10.1056/nejmoa1807315
31. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ,
Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple
human cancers and is counterbalanced by CD47. Sci Transl Med (2010) 2:63ra94.
doi: 10.1126/scitranslmed.3001375
52. Clohessy JG, Pandolfi PP. Mouse hospital and co-clinical trial project—from
bench to bedside. Nat Rev Clin Oncol (2015) 12:491–8. doi: 10.1038/nrclinonc.2015.62
32. Ma R-Y, Black A, Qian B-Z. Macrophage diversity in cancer revisited in the era
of single-cell omics. Trends Immunol (2022) 43:546–63. doi: 10.1016/j.it.2022.04.008
53. Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, et al. Selective
SIRPa blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy
resistance. J Clin Invest (2020) 130:6109–23. doi: 10.1172/jci135528
33. Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, et al. Highdimensional analysis delineates myeloid and lymphoid compartment remodeling
during successful immune-checkpoint cancer therapy. Cell (2018) 175:1014–
1030.e19. doi: 10.1016/j.cell.2018.09.030
54. Martinov T, McKenna KM, Tan WH, Collins EJ, Kehret AR, Linton JD, et al.
Building the next generation of humanized hemato-lymphoid system mice. Front
Immunol (2021) 12:643852. doi: 10.3389/fimmu.2021.643852
34. Mulder K, Patel AA, Kong WT, Piot C, Halitzki E, Dunsmore G, et al. Crosstissue single-cell landscape of human monocytes and macrophages in health and
disease. Immunity (2021) 54:1883–1900.e5. doi: 10.1016/j.immuni.2021.07.007
55. Li Y, Mention J, Court N, Masse-Ranson G, Toubert A, Spits H, et al. A novel
Flt3-deficient HIS mouse model with selective enhancement of human DC
development. Eur J Immunol (2016) 46:1291–9. doi: 10.1002/eji.201546132
35. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al.
Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med (2018)
378:1396–407. doi: 10.1056/nejmoa1801445
56. Xu MM, Pu Y, Han D, Shi Y, Cao X, Liang H, et al. Dendritic cells but not
macrophages sense tumor mitochondrial DNA for Cross-priming through signal
regulatory protein a signaling. Immunity (2017) 47:363–373.e5. doi: 10.1016/
j.immuni.2017.07.016
36. Hashwah H, Bertram K, Stirm K, Stelling A, Wu C, Kasser S, et al. The IL-6
signaling complex is a critical driver, negative prognostic factor, and therapeutic target
Frontiers in Immunology
16
frontiersin.org
...
論文の公開元へ
